131 related articles for article (PubMed ID: 31578654)
1. Retrospective analysis by site of primary tumor of patients with unresectable locally-advanced or metastatic pancreatic adenocarcinoma receiving chemotherapy.
Colloca GA; Venturino A; Guarneri D
Clin Exp Metastasis; 2019 Dec; 36(6):519-525. PubMed ID: 31578654
[TBL] [Abstract][Full Text] [Related]
2. Second-generation inflammation-related scores are more effective than systemic inflammation ratios in predicting prognosis of patients with unresectable or metastatic pancreatic cancer receiving cytotoxic chemotherapy.
Colloca GA; Venturino A; Guarneri D
Med Oncol; 2018 Oct; 35(12):158. PubMed ID: 30374617
[TBL] [Abstract][Full Text] [Related]
3. Tumor growth kinetics by CA 19-9 in patients with unresectable pancreatic cancer receiving chemotherapy: A retrospective analysis.
Colloca GA; Venturino A; Guarneri D
Pancreatology; 2020 Sep; 20(6):1189-1194. PubMed ID: 32747196
[TBL] [Abstract][Full Text] [Related]
4. Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile?
Buc E; Orry D; Antomarchi O; Gagnière J; Da Ines D; Pezet D
World J Surg Oncol; 2014 Nov; 12():347. PubMed ID: 25407113
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome of patients with advanced pancreatic cancer treated with sequential chemotherapies before the era of modern combination therapy protocols.
Abendroth A; Noureddine R; Abramczyk M; Paul A; Gerken G; Schmid KW; Markus P; Schumacher B; Wiesweg M; Köhler J; Markus M; Mende B; Dechêne A; Schuler M; Kasper S
J Cancer Res Clin Oncol; 2019 Feb; 145(2):445-455. PubMed ID: 30430229
[TBL] [Abstract][Full Text] [Related]
6. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial.
Bockorny B; Semenisty V; Macarulla T; Borazanci E; Wolpin BM; Stemmer SM; Golan T; Geva R; Borad MJ; Pedersen KS; Park JO; Ramirez RA; Abad DG; Feliu J; Muñoz A; Ponz-Sarvise M; Peled A; Lustig TM; Bohana-Kashtan O; Shaw SM; Sorani E; Chaney M; Kadosh S; Vainstein Haras A; Von Hoff DD; Hidalgo M
Nat Med; 2020 Jun; 26(6):878-885. PubMed ID: 32451495
[TBL] [Abstract][Full Text] [Related]
7. Association between primary origin (head, body and tail) of metastasised pancreatic ductal adenocarcinoma and oncologic outcome: A population-based analysis.
Mackay TM; van Erning FN; van der Geest LGM; de Groot JWB; Haj Mohammad N; Lemmens VE; van Laarhoven HW; Besselink MG; Wilmink JW;
Eur J Cancer; 2019 Jan; 106():99-105. PubMed ID: 30476732
[TBL] [Abstract][Full Text] [Related]
8. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.
Wang-Gillam A; Hubner RA; Siveke JT; Von Hoff DD; Belanger B; de Jong FA; Mirakhur B; Chen LT
Eur J Cancer; 2019 Feb; 108():78-87. PubMed ID: 30654298
[TBL] [Abstract][Full Text] [Related]
9. FOLFIRINOX in patients with peritoneal carcinomatosis from pancreatic adenocarcinoma: a retrospective study.
Bonnet E; Mastier C; Lardy-Cléaud A; Rochefort P; Sarabi M; Guibert P; Cattey-Javouhey A; Desseigne F; de La Fouchardière C
Curr Oncol; 2019 Aug; 26(4):e466-e472. PubMed ID: 31548814
[TBL] [Abstract][Full Text] [Related]
10. Downstaging in Stage IV Pancreatic Cancer: A New Population Eligible for Surgery?
Frigerio I; Regi P; Giardino A; Scopelliti F; Girelli R; Bassi C; Gobbo S; Martini PT; Capelli P; D'Onofrio M; Malleo G; Maggino L; Viviani E; Butturini G
Ann Surg Oncol; 2017 Aug; 24(8):2397-2403. PubMed ID: 28516291
[TBL] [Abstract][Full Text] [Related]
11. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.
Stein SM; James ES; Deng Y; Cong X; Kortmansky JS; Li J; Staugaard C; Indukala D; Boustani AM; Patel V; Cha CH; Salem RR; Chang B; Hochster HS; Lacy J
Br J Cancer; 2016 Mar; 114(7):737-43. PubMed ID: 27022826
[TBL] [Abstract][Full Text] [Related]
12. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.
Nitsche U; Wenzel P; Siveke JT; Braren R; Holzapfel K; Schlitter AM; Stöß C; Kong B; Esposito I; Erkan M; Michalski CW; Friess H; Kleeff J
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1212-20. PubMed ID: 26350368
[TBL] [Abstract][Full Text] [Related]
13. Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S-1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma.
Akahori T; Sho M; Yanagimoto H; Satoi S; Nagai M; Nishiwada S; Nakagawa K; Nakamura K; Yamamoto T; Hirooka S; Yamaki S; Ikeda N
Oncologist; 2019 Jun; 24(6):749-e224. PubMed ID: 30679316
[TBL] [Abstract][Full Text] [Related]
14. Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer.
Haas M; Laubender RP; Stieber P; Holdenrieder S; Bruns CJ; Wilkowski R; Mansmann U; Heinemann V; Boeck S
Tumour Biol; 2010 Aug; 31(4):351-7. PubMed ID: 20480409
[TBL] [Abstract][Full Text] [Related]
15. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological features and treatment outcomes of metastatic or locally unresectable small bowel adenocarcinoma.
Li X; Ying H; Cheng Y; Zhao L; Zhao S; Bai C; Zhou J
J BUON; 2019; 24(6):2539-2545. PubMed ID: 31983130
[TBL] [Abstract][Full Text] [Related]
17. Long term survivors with metastatic pancreatic cancer treated with gemcitabine alone or plus cisplatin: a retrospective analysis of an Anatolian Society of Medical Oncology multicenter study.
Inal A; Ciltas A; Yildiz R; Berk V; Kos FT; Dane F; Unek IT; Colak D; Ozdemir NY; Buyukberber S; Gumus M; Ozkan M; Isikdogan A
Asian Pac J Cancer Prev; 2012; 13(5):1841-4. PubMed ID: 22901133
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors in first-line chemotherapy treated metastatic gastric cancer patients: a retrospective study.
Inal A; Kaplan MA; Kuçukoner M; Urakci Z; Guven M; Nas N; Yunce M; Işikdogan A
Asian Pac J Cancer Prev; 2012; 13(8):3869-72. PubMed ID: 23098485
[TBL] [Abstract][Full Text] [Related]
19. Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer.
Novarino A; Satolli MA; Chiappino I; Giacobino A; Bellone G; Rahimi F; Milanesi E; Bertetto O; Ciuffreda L
Am J Clin Oncol; 2009 Feb; 32(1):44-8. PubMed ID: 19194124
[TBL] [Abstract][Full Text] [Related]
20. Neutrophil count and the inflammation-based glasgow prognostic score predict survival in patients with advanced gastric cancer receiving first-line chemotherapy.
Li QQ; Lu ZH; Yang L; Lu M; Zhang XT; Li J; Zhou J; Wang XC; Gong JF; Gao J; Li J; Li Y; Shen L
Asian Pac J Cancer Prev; 2014; 15(2):945-50. PubMed ID: 24568523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
